1 Study Coverage 1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product Introduction 1.2 Market by Type 1.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Inhalation 1.2.3 Injectables 1.2.4 Oral Administration 1.3 Market by Application 1.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Other 1.4 Study Objectives 1.5 Years Considered 2 Executive Summary 2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Estimates and Forecasts 2017-2028 2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Estimates and Forecasts 2017-2028 2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2017 VS 2021 VS 2028 2.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region 2.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) 2.4.2 Global Sales Pulmonary Arterial Hypertension (PAH) Drugs by Region (2023-2028) 2.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region 2.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) 2.5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) 2.6 North America 2.7 Europe 2.8 Asia-Pacific 2.9 Latin America 2.10 Middle East & Africa 3 Competition by Manufacturers 3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers 3.1.1 Global Top Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers by Sales (2017-2022) 3.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2017-2022) 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs in 2021 3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers 3.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2017-2022) 3.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Manufacturers (2017-2022) 3.2.3 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2021 3.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Price by Manufacturers (2017-2022) 3.4 Analysis of Competitive Landscape 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Geographical Distribution 3.5 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type 4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type 4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Sales by Type (2017-2022) 4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Sales by Type (2023-2028) 4.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) 4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type 4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Revenue by Type (2017-2022) 4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Revenue by Type (2023-2028) 4.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) 4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type 4.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2022) 4.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2023-2028) 5 Market Size by Application 5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application 5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Sales by Application (2017-2022) 5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Sales by Application (2023-2028) 5.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) 5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application 5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Historical Revenue by Application (2017-2022) 5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Forecasted Revenue by Application (2023-2028) 5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) 5.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application 5.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2022) 5.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2023-2028) 6 North America 6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type 6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) 6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028) 6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application 6.2.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) 6.2.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028) 6.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country 6.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2028) 6.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028) 6.3.3 U.S. 6.3.4 Canada 7 Europe 7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type 7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) 7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028) 7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application 7.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) 7.2.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028) 7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country 7.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2028) 7.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028) 7.3.3 Germany 7.3.4 France 7.3.5 U.K. 7.3.6 Italy 7.3.7 Russia 8 Asia Pacific 8.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type 8.1.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) 8.1.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028) 8.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application 8.2.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) 8.2.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028) 8.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region 8.3.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2028) 8.3.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2028) 8.3.3 China 8.3.4 Japan 8.3.5 South Korea 8.3.6 India 8.3.7 Australia 8.3.8 Taiwan 8.3.9 Indonesia 8.3.10 Thailand 8.3.11 Malaysia 8.3.12 Philippines 9 Latin America 9.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type 9.1.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) 9.1.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028) 9.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application 9.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) 9.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028) 9.3 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country 9.3.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2028) 9.3.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028) 9.3.3 Mexico 9.3.4 Brazil 9.3.5 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type 10.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2028) 10.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2028) 10.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application 10.2.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2028) 10.2.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2028) 10.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Country 10.3.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2028) 10.3.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2028) 10.3.3 Turkey 10.3.4 Saudi Arabia 11 Company Profiles 11.1 Pfizer 11.1.1 Pfizer Corporation Information 11.1.2 Pfizer Overview 11.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.1.5 Pfizer Recent Developments 11.2 Glaxosmithkline 11.2.1 Glaxosmithkline Corporation Information 11.2.2 Glaxosmithkline Overview 11.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.2.5 Glaxosmithkline Recent Developments 11.3 Novartis 11.3.1 Novartis Corporation Information 11.3.2 Novartis Overview 11.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.3.5 Novartis Recent Developments 11.4 United Therapeutics 11.4.1 United Therapeutics Corporation Information 11.4.2 United Therapeutics Overview 11.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.4.5 United Therapeutics Recent Developments 11.5 AstraZeneca 11.5.1 AstraZeneca Corporation Information 11.5.2 AstraZeneca Overview 11.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.5.5 AstraZeneca Recent Developments 11.6 Merck 11.6.1 Merck Corporation Information 11.6.2 Merck Overview 11.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.6.5 Merck Recent Developments 11.7 Bayer Healthcare 11.7.1 Bayer Healthcare Corporation Information 11.7.2 Bayer Healthcare Overview 11.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.7.5 Bayer Healthcare Recent Developments 11.8 Actelion Pharmaceuticals 11.8.1 Actelion Pharmaceuticals Corporation Information 11.8.2 Actelion Pharmaceuticals Overview 11.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.8.5 Actelion Pharmaceuticals Recent Developments 11.9 Daiichi Sankyo 11.9.1 Daiichi Sankyo Corporation Information 11.9.2 Daiichi Sankyo Overview 11.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.9.5 Daiichi Sankyo Recent Developments 11.10 Northern Therapeutics 11.10.1 Northern Therapeutics Corporation Information 11.10.2 Northern Therapeutics Overview 11.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.10.5 Northern Therapeutics Recent Developments 11.11 Aires Pharmaceuticals 11.11.1 Aires Pharmaceuticals Corporation Information 11.11.2 Aires Pharmaceuticals Overview 11.11.3 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.11.4 Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.11.5 Aires Pharmaceuticals Recent Developments 11.12 Arena Pharmaceuticals 11.12.1 Arena Pharmaceuticals Corporation Information 11.12.2 Arena Pharmaceuticals Overview 11.12.3 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.12.4 Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.12.5 Arena Pharmaceuticals Recent Developments 11.13 Berlin Cures 11.13.1 Berlin Cures Corporation Information 11.13.2 Berlin Cures Overview 11.13.3 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.13.4 Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.13.5 Berlin Cures Recent Developments 11.14 Eiger BioPharmaceuticals 11.14.1 Eiger BioPharmaceuticals Corporation Information 11.14.2 Eiger BioPharmaceuticals Overview 11.14.3 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.14.4 Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.14.5 Eiger BioPharmaceuticals Recent Developments 11.15 Reata Pharmaceuticals 11.15.1 Reata Pharmaceuticals Corporation Information 11.15.2 Reata Pharmaceuticals Overview 11.15.3 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Price, Revenue and Gross Margin (2017-2022) 11.15.4 Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications 11.15.5 Reata Pharmaceuticals Recent Developments 12 Industry Chain and Sales Channels Analysis 12.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Chain Analysis 12.2 Pulmonary Arterial Hypertension (PAH) Drugs Key Raw Materials 12.2.1 Key Raw Materials 12.2.2 Raw Materials Key Suppliers 12.3 Pulmonary Arterial Hypertension (PAH) Drugs Production Mode & Process 12.4 Pulmonary Arterial Hypertension (PAH) Drugs Sales and Marketing 12.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales Channels 12.4.2 Pulmonary Arterial Hypertension (PAH) Drugs Distributors 12.5 Pulmonary Arterial Hypertension (PAH) Drugs Customers 13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis 13.1 Pulmonary Arterial Hypertension (PAH) Drugs Industry Trends 13.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers 13.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges 13.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints 14 Key Findings in The Global Pulmonary Arterial Hypertension (PAH) Drugs Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Author Details 15.3 Disclaimer

List of Tables Table 1. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million) Table 2. Major Manufacturers of Inhalation Table 3. Major Manufacturers of Injectables Table 4. Major Manufacturers of Oral Administration Table 5. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million) Table 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million) Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) & (K Pcs) Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2022) Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2023-2028) & (K Pcs) Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2023-2028) Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) & (US$ Million) Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2017-2022) Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) & (US$ Million) Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2023-2028) Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (2017-2022) & (K Pcs) Table 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturers (2017-2022) Table 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2017-2022) & (US$ Million) Table 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2017-2022) Table 19. Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers (2017-2022) &(USD/Pcs) Table 20. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 21. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2021) Table 22. Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution and Headquarters Table 23. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Offered Table 24. Date of Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2017-2022) Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2023-2028) Table 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2017-2022) Table 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2023-2028) Table 34. Pulmonary Arterial Hypertension (PAH) Drugs Price by Type (2017-2022) & (USD/Pcs) Table 35. Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Type (2023-2028) & (USD/Pcs) Table 36. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 37. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 38. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2017-2022) Table 39. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2023-2028) Table 40. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 41. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 42. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2017-2022) Table 43. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Application (2023-2028) Table 44. Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2017-2022) & (USD/Pcs) Table 45. Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2023-2028) & (USD/Pcs) Table 46. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 47. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 48. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 49. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 50. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 51. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 52. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 53. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 54. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs) Table 55. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs) Table 56. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (US$ Million) Table 57. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (US$ Million) Table 58. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 59. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 60. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 61. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 62. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 63. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 64. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 65. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 66. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs) Table 67. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs) Table 68. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (US$ Million) Table 69. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (US$ Million) Table 70. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 71. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 72. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 73. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 74. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 75. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 76. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 77. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 78. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2017-2022) & (K Pcs) Table 79. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2023-2028) & (K Pcs) Table 80. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2017-2022) & (US$ Million) Table 81. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2023-2028) & (US$ Million) Table 82. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 83. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 84. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 85. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 86. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 87. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 88. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 89. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 90. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs) Table 91. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs) Table 92. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (US$ Million) Table 93. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (US$ Million) Table 94. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2017-2022) & (K Pcs) Table 95. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2023-2028) & (K Pcs) Table 96. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2017-2022) & (US$ Million) Table 97. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2023-2028) & (US$ Million) Table 98. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2017-2022) & (K Pcs) Table 99. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2023-2028) & (K Pcs) Table 100. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2017-2022) & (US$ Million) Table 101. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2023-2028) & (US$ Million) Table 102. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2017-2022) & (K Pcs) Table 103. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2023-2028) & (K Pcs) Table 104. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2017-2022) & (US$ Million) Table 105. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2023-2028) & (US$ Million) Table 106. Pfizer Corporation Information Table 107. Pfizer Description and Major Businesses Table 108. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 109. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 110. Pfizer Recent Developments Table 111. Glaxosmithkline Corporation Information Table 112. Glaxosmithkline Description and Major Businesses Table 113. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 114. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 115. Glaxosmithkline Recent Developments Table 116. Novartis Corporation Information Table 117. Novartis Description and Major Businesses Table 118. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 119. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 120. Novartis Recent Developments Table 121. United Therapeutics Corporation Information Table 122. United Therapeutics Description and Major Businesses Table 123. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 124. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 125. United Therapeutics Recent Developments Table 126. AstraZeneca Corporation Information Table 127. AstraZeneca Description and Major Businesses Table 128. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 129. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 130. AstraZeneca Recent Developments Table 131. Merck Corporation Information Table 132. Merck Description and Major Businesses Table 133. Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 134. Merck Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 135. Merck Recent Developments Table 136. Bayer Healthcare Corporation Information Table 137. Bayer Healthcare Description and Major Businesses Table 138. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 139. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 140. Bayer Healthcare Recent Developments Table 141. Actelion Pharmaceuticals Corporation Information Table 142. Actelion Pharmaceuticals Description and Major Businesses Table 143. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 144. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 145. Actelion Pharmaceuticals Recent Developments Table 146. Daiichi Sankyo Corporation Information Table 147. Daiichi Sankyo Description and Major Businesses Table 148. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 149. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 150. Daiichi Sankyo Recent Developments Table 151. Northern Therapeutics Corporation Information Table 152. Northern Therapeutics Description and Major Businesses Table 153. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 154. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 155. Northern Therapeutics Recent Developments Table 156. Aires Pharmaceuticals Corporation Information Table 157. Aires Pharmaceuticals Description and Major Businesses Table 158. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 159. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 160. Aires Pharmaceuticals Recent Developments Table 161. Arena Pharmaceuticals Corporation Information Table 162. Arena Pharmaceuticals Description and Major Businesses Table 163. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 164. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 165. Arena Pharmaceuticals Recent Developments Table 166. Berlin Cures Corporation Information Table 167. Berlin Cures Description and Major Businesses Table 168. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 169. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 170. Berlin Cures Recent Developments Table 171. Eiger BioPharmaceuticals Corporation Information Table 172. Eiger BioPharmaceuticals Description and Major Businesses Table 173. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 174. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 175. Eiger BioPharmaceuticals Recent Developments Table 176. Reata Pharmaceuticals Corporation Information Table 177. Reata Pharmaceuticals Description and Major Businesses Table 178. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022) Table 179. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications Table 180. Reata Pharmaceuticals Recent Developments Table 181. Key Raw Materials Lists Table 182. Raw Materials Key Suppliers Lists Table 183. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List Table 184. Pulmonary Arterial Hypertension (PAH) Drugs Customers List Table 185. Pulmonary Arterial Hypertension (PAH) Drugs Market Trends Table 186. Pulmonary Arterial Hypertension (PAH) Drugs Market Drivers Table 187. Pulmonary Arterial Hypertension (PAH) Drugs Market Challenges Table 188. Pulmonary Arterial Hypertension (PAH) Drugs Market Restraints Table 189. Research Programs/Design for This Report Table 190. Key Data Information from Secondary Sources Table 191. Key Data Information from Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture Figure 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Type in 2021 & 2028 Figure 3. Inhalation Product Picture Figure 4. Injectables Product Picture Figure 5. Oral Administration Product Picture Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Application in 2021 & 2028 Figure 7. Hospitals Figure 8. Clinics Figure 9. Other Figure 10. Pulmonary Arterial Hypertension (PAH) Drugs Report Years Considered Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2017-2028 (K Pcs) Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2017-2028 (US$ Million) Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028 Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2017-2022) Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2023-2028) Figure 17. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2017-2028) & (K Pcs) Figure 18. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 19. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2017-2028) & (K Pcs) Figure 20. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 21. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2017-2028) & (K Pcs) Figure 22. Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 23. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2017-2028) & (K Pcs) Figure 24. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 25. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales YoY (2017-2028) & (K Pcs) Figure 26. Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue YoY (2017-2028) & (US$ Million) Figure 27. The Pulmonary Arterial Hypertension (PAH) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021 Figure 28. The Top 5 and 10 Largest Manufacturers of Pulmonary Arterial Hypertension (PAH) Drugs in the World: Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2021 Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021 Figure 30. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 31. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 32. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 33. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 34. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 35. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 36. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 37. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 38. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2017-2028) Figure 39. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2017-2028) Figure 40. U.S. Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 41. Canada Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 42. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 43. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 44. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 46. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2017-2028) Figure 47. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2017-2028) Figure 48. Germany Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 49. France Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 50. U.K. Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 51. Italy Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 52. Russia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 53. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 54. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 55. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 56. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 57. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Region (2017-2028) Figure 58. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Region (2017-2028) Figure 59. China Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 60. Japan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 61. South Korea Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 62. India Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 63. Australia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 64. Taiwan Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 65. Indonesia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 66. Thailand Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 67. Malaysia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 68. Philippines Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 69. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 70. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 71. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 72. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 73. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2017-2028) Figure 74. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2017-2028) Figure 75. Mexico Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 76. Brazil Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 77. Argentina Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 78. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2017-2028) Figure 79. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2017-2028) Figure 80. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2017-2028) Figure 81. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2017-2028) Figure 82. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Country (2017-2028) Figure 83. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Country (2017-2028) Figure 84. Turkey Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 85. Saudi Arabia Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 86. U.A.E Pulmonary Arterial Hypertension (PAH) Drugs Revenue (2017-2028) & (US$ Million) Figure 87. Pulmonary Arterial Hypertension (PAH) Drugs Value Chain Figure 88. Pulmonary Arterial Hypertension (PAH) Drugs Production Process Figure 89. Channels of Distribution Figure 90. Distributors Profiles Figure 91. Bottom-up and Top-down Approaches for This Report Figure 92. Data Triangulation Figure 93. Key Executives Interviewed

Pfizer Glaxosmithkline Novartis United Therapeutics AstraZeneca Merck Bayer Healthcare Actelion Pharmaceuticals Daiichi Sankyo Northern Therapeutics Aires Pharmaceuticals Arena Pharmaceuticals Berlin Cures Eiger BioPharmaceuticals Reata Pharmaceuticals